• Basic Info
• Top Questions
• Clinical Info
• Interactions

Uses

Testicular Cancer

Component of various combination chemotherapeutic regimens for treatment of refractory testicular tumors in patients who have already received appropriate surgery, chemotherapy, and radiation therapy.

Component of various combination chemotherapeutic regimens with cisplatin for first-line treatment of stage III or unresectable stage II nonseminomatous testicular carcinoma and for chemotherapy-refractory disease.

Combination chemotherapy with etoposide, cisplatin, and bleomycin (BEP) is recommended for initial treatment of advanced nonseminomatous testicular carcinoma.

Component of a combination chemotherapeutic regimen (ifosfamide, cisplatin, and either etoposide or vinblastine) as second-line therapy for recurrent nonseminomatous testicular carcinoma.

Component of combination chemotherapeutic regimens (with cisplatin) for initial treatment of disseminated seminoma testis and treatment-refractory disease.

Component of combination chemotherapeutic regimens (usually with cisplatin) for initial treatment of advanced extragonadal germ-cell tumors.

Small Cell Lung Cancer

Component of a combination chemotherapeutic regimen with etoposide and cisplatin or carboplatin (PE) as a preferred first-line treatment of small-cell lung cancer.

In combination with ifosfamide with mesna and cisplatin (VIP) or carboplatin (ICE) as second-line therapy for the treatment of refractory small-cell lung cancer.

In combination with cyclophosphamide and doxorubicin (or vincristine) for treatment of extensive-stage disease.

Non-small Cell Lung Cancer

Combination chemotherapy with etoposide and cisplatin has been used for second-line treatment of advanced non-small cell lung cancer†, but paclitaxel-containing or other platinum-based regimens currently are preferred.

Hodgkin's Disease

Component of combination chemotherapeutic regimens for treatment of advanced or refractory Hodgkin's lymphoma†.

Non-Hodgkin's Lymphoma

Component of various combination chemotherapeutic regimens for treatment of advanced non-Hodgkin's lymphoma†.

Component of combination chemotherapeutic regimens (e.g., etoposide, ifosfamide, and methotrexate) for treatment of advanced diffuse lymphomas of unfavorable histology (e.g., diffuse histiocytic lymphoma)†.

Cutaneous T-cell Lymphoma

Has been used with transient responses in patients with cutaneous T-cell lymphoma (mycosis fungoides†).

Acute Myeloid Leukemia

Used alone and in various combination chemotherapeutic regimens for treatment of refractory acute myeloid (myelogenous, nonlymphocytic) leukemia (AML, ANLL)† in adults and children.

Particularly effective for the treatment of acute monocytic and myelomonocytic leukemias†; may be useful when monocytoid cells are not cleared with conventional combination chemotherapy.

Acute Lymphocytic Leukemia

Has been used alone and in combination chemotherapy for remission induction in refractory acute lymphocytic (lymphoblastic) leukemia (ALL)† in a limited number of children; little, if any, activity in adults.

Wilms' Tumor

Component of a combination chemotherapeutic regimen (e.g., carboplatin with etoposide) as second-line (salvage) therapy for treatment of recurrent (relapsed or refractory) Wilms' tumor† including recurrent tumors of unfavorable histology, abdominal recurrence after radiation therapy, or recurrence within 6 months of nephrectomy or after initial combination chemotherapy.

Alternative to standard preferred regimens in patients with less severe stages of Wilms’ tumor†.

Second-line high-dose therapy followed by autologous bone marrow transplantation also has been used effectively in recurrent disease.

Offer patients with recurrent disease (i.e., salvage therapy failure) treatment under protocol conditions in ongoing clinical trials.

Neuroblastoma

Component of combination chemotherapeutic regimens (cyclophosphamide, doxorubicin, cisplatin, and/or etoposide or teniposide) as preferred first-line therapy for neuroblastoma†.

Kaposi's Sarcoma

Used alone or in combination chemotherapeutic regimens as second-line therapy for palliative treatment of AIDS-related Kaposi's sarcoma†.

Ovarian Cancer

Has been used orally as second-line therapy for advanced epithelial ovarian cancer†.

Component of a combination chemotherapeutic regimen with bleomycin and cisplatin (BEP) as first-line therapy for ovarian germ cell tumors†.

Other Uses

Component of alternating chemotherapeutic regimens (vincristine, doxorubicin and cyclophosphamide alternating with ifosfamide and mesna and etoposide) as first-line therapy for Ewing's sarcoma†.

Component of a chemotherapeutic regimen with methotrexate, dactinomycin, cyclophosphamide, and vincristine (EMA-CO), or with cisplatin as second-line therapy for gestational trophoblastic tumors† (choriocarcinoma†). Also has been used for treatment of chorioadenoma destruens†.

May be useful for treatment of hepatoma†.

May be useful as second-line therapy for treatment of rhabdomyosarcoma†.